文献速递脊柱关节炎

早期中轴型脊柱关节炎持续缓解后塞妥珠单抗剂量递减的维持策略

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
PubMed 文献 · Ann Rheum Dis · 2020-05-07

C-OPTIMISE 是一项两部分、多中心 3b 期研究,纳入早期活动性中轴型脊柱关节炎成人患者,开放标签诱导期接受塞妥珠单抗 200 mg 每 2 周治疗 48 周,持续缓解者随机进入双盲维持期,比较全剂量、减剂量与安慰剂撤退。结果显示减剂量组与全剂量组无 flare 比例相近,均显著高于安慰剂组,提示持续缓解后可减量但不应完全停药。

要点

  • 早期 axSpA 持续缓解者减剂量维持无 flare 比例与全剂量相近。
  • 塞妥珠单抗完全撤退后 flare 风险高,不应停药。
  • 放射学与非放射学 axSpA 患者的应答具有可比性。

核心结论

  • 早期 axSpA 患者在第 48 周达到持续缓解后可减少塞妥珠单抗维持剂量。
  • 由于停药后 flare 风险高,不应完全停用塞妥珠单抗。

研究设计与样本

  • C-OPTIMISE 为两部分、多中心 3b 期研究,纳入早期活动性 axSpA 成人患者(放射学或非放射学)。
  • 开放标签诱导期 48 周接受塞妥珠单抗 200 mg 每 2 周,持续缓解者随机进入 48 周双盲维持期。

主要发现

  • 第 48 周 43.9%(323/736)患者达到持续缓解,其中 313 例被随机分组。
  • 第 48 至 96 周,全剂量组、减剂量组与安慰剂组无 flare 比例分别为 83.7%(87/104)、79.0%(83/105)和 20.2%(21/104)。
  • 两个塞妥珠单抗组与安慰剂组比较的 p<0.001。
  • 放射学与非放射学 axSpA 患者的应答具有可比性。

关键数值与推荐

  • 持续缓解定义为第 32/36 周和第 48 周 ASDAS<1.3。
  • flare 定义为连续两次访视 ASDAS≥2.1 或任意时间点 ASDAS>3.5。
  • 全剂量为塞妥珠单抗 200 mg 每 2 周,减剂量为 200 mg 每 4 周。

临床怎么用

  • 对达到持续缓解的早期 axSpA 患者可考虑塞妥珠单抗减剂量维持。
  • 应避免完全停用塞妥珠单抗,以降低 flare 风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained remission in patients with early axSpA. METHODS: C-OPTIMISE was a two-part, multicentre phase 3b study in adults with early active axSpA (radiographic or non-radiographic). During the 48-week open-label induction period, patients received CZP 200 mg every 2 weeks (Q2W). At Week 48, patients in sustained remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 at Weeks 32/36 and 48) were randomised to double-blind CZP 200 mg Q2W (full maintenance dose), CZP 200 mg every 4 weeks (Q4W; reduced maintenance dose) or placebo (withdrawal) for a further 48 weeks. The primary endpoint was remaining flare-free (flare: ASDAS ≥2.1 at two consecutive visits or ASDAS >3.5 at any time point) during the double-blind period. RESULTS: At Week 48, 43.9% (323/736) patients achieved sustained remission, of whom 313 were randomised to CZP full maintenance dose, CZP reduced maintenance dose or placebo. During Weeks 48 to 96, 83.7% (87/104), 79.0% (83/105) and 20.2% (21/104) of patients receiving the full maintenance dose, reduced maintenance dose or placebo, respectively, were flare-free (p<0.001 vs placebo in both CZP groups). Responses in radiographic and non-radiographic axSpA patients were comparable. CONCLUSIONS: Patients with early axSpA who achieve sustained remission at 48 weeks can reduce their CZP maintenance dose; however, treatment should not be completely discontinued due to the high risk of flare following CZP withdrawal. TRIAL REGISTRATION NUMBER: NCT02505542, ClinicalTrials.gov.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Landewé RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020. PMID: 32381562. doi:10.1136/annrheumdis-2019-216839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。